Has Stephen Ikeda, MD received payments from drug or device companies?

Yes. Drug and device makers reported $221 in general payments to Stephen Ikeda, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Ikeda, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Ikeda, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Ikeda, MD

Child & Adolescent Psychiatry · Plymouth, MANPI 1619900198

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $147 of the $221 with a category attached, or 66.5%. 3 manufacturers reported payments, led by AbbVie at 54.9% of the total. 2025 is the largest year on record at $146, 2.4 times the $62 reported in 2021.

$221in general payments, 2019–2025

Across 9 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$121
E.r. Squibb & Sons, L.L.C.$53
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47

What the payments were for

Food & beverage$14766%
Education$7434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	6	$121
E.r. Squibb & Sons, L.L.C.	2	$53
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$47

How this compares

$221 in reported general payments places this provider in the 60th percentile of 104 child & adolescent psychiatry providers in Massachusetts.

See all child & adolescent psychiatry providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$370,836

Medicare patients

172

Services billed

2,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega TrinzaPaliperidone Palmitate	14	$105,456
Invega SustennaPaliperidone Palmitate	31	$103,522
CaplytaLumateperone Tosylate	59	$103,133
VraylarCariprazine Hcl	38	$71,685
SpravatoEsketamine Hcl	32	$65,139
RexultiBrexpiprazole	31	$55,889
LybalviOlanzapine/Samidorphan Malate	24	$50,007
ClozarilClozapine	26	$38,321
TrintellixVortioxetine Hydrobromide	45	$28,797
AristadaAripiprazole Lauroxil	13	$28,655
Aripiprazole	136	$28,356
Risperidone ErRisperidone Microspheres	12	$24,454
Clozapine	356	$14,785
Adderall XrDextroamphetamine/Amphetamine	18	$11,428
NuedextaDextromethorphan Hbr/Quinidine	13	$10,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$47	$103,13359 claims
AbbVieVraylar	$121	$71,68538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 104 child & adolescent psychiatry providers in Massachusetts.

Other child & adolescent psychiatry in Plymouth

Maitri PatelFramingham$277K
David DemasoBoston$41K
Blaise AguirreBelmont$21K
Matthew SiegelBoston$11K
Janet WozniakBoston$8K
Joseph Gonzalez HeydrichBoston$7K
Michael MarcusBoston$4K
Ranna ParekhBoston$3K
Joseph BiedermanBoston$3K
Ireen AhmedBoston$3K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →